-- title: "Feline Leukemia Virus (FeLV) and Feline Immunodeficiency Virus (FIV): Point-of-Care Testing and Clinical Management" category: "emerging-tech" metaDescription: "A technical review of point-of-care diagnostics for FeLV and FIV, comparing SNAP ELISA, PCR, and lateral flow assays, with guidance on discordant results and therapeutic management." primaryKeyword: "FeLV FIV point-of-care testing" secondaryKeywords: ["feline retrovirus diagnostics", "SNAP ELISA", "feline immunodeficiency virus PCR", "lateral flow assay feline", "FeLV p27 antigen", "FIV antibody testing", "discordant retrovirus results", "feline antiviral therapy", "feline immunomodulators"]

Feline Leukemia Virus (FeLV) and Feline Immunodeficiency Virus (FIV): Point-of-Care Testing and Clinical Management

Introduction

Feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) are globally distributed retroviruses of domestic cats (Felis catus) with significant implications for morbidity, mortality, and clinical decision making. FeLV, a gammaretrovirus, causes progressive immunosuppression, anemia, and lymphoma, while FIV, a lentivirus, induces a gradual decline in CD4+ T lymphocyte counts leading to acquired immunodeficiency syndrome-like pathology. Accurate and timely diagnosis of these infections is critical for implementing management strategies, preventing transmission, and guiding therapeutic interventions. Point-of-care (POC) testing technologies have become the cornerstone of feline retrovirus screening in veterinary practice, offering rapid turnaround times and operational simplicity. This article provides a detailed technical comparison of the three principal POC modalities: SNAP enzyme-linked immunosorbent assay (ELISA), polymerase chain reaction (PCR), and lateral flow immunoassays. It further addresses the interpretation of discordant results and reviews current therapeutic options including antiviral agents and immunomodulators.

Biological Basis of FeLV and FIV Infection

FeLV is transmitted primarily through saliva, nasal secretions, and blood, with oronasal exposure being the most common route. The virus targets hematopoietic cells, lymphoid tissues, and epithelial cells via the thiamine transporter THTR1. Infection can follow one of several outcomes: abortive, regressive, latent, or progressive. Progressive infection is characterized by persistent viremia, high p27 antigen levels, and a poor prognosis. Regressive infection involves transient viremia followed by proviral integration without sustained antigen production. Latent infection features proviral DNA in bone marrow without detectable antigenemia.

FIV is transmitted predominantly through bite wounds, with the virus establishing infection in CD4+ T lymphocytes, macrophages, and dendritic cells via the CD134 receptor and CXCR4 coreceptor. The infection progresses through acute, asymptomatic, and terminal phases. The acute phase is marked by fever, lymphadenopathy, and neutropenia. The asymptomatic phase can last years, during which viral load remains detectable but clinical signs are absent. The terminal phase involves severe immunosuppression, opportunistic infections, and neoplasia.

Point-of-Care Testing Modalities

SNAP ELISA

The SNAP ELISA is a solid-phase immunoassay designed for the simultaneous detection of FeLV p27 antigen and FIV antibodies (anti-p24 antibodies) in feline whole blood, serum, or plasma. The assay uses a membrane-bound capture system with enzyme-labeled detection antibodies. The sample is mixed with conjugate and flows across a matrix containing immobilized antigens and antibodies. A colorimetric signal develops upon binding of the enzyme-substrate complex. The SNAP ELISA provides results within 10 minutes and has reported sensitivity and specificity exceeding 98% for FeLV p27 antigen detection and 95% for FIV antibody detection in high-prevalence populations [1, 9]. However, the assay cannot distinguish between progressive and regressive FeLV infection, as p27 antigen may be transiently present in regressive cases. False-positive FIV results can occur in kittens with maternal antibodies, and false-negative results may arise during the acute phase of FIV infection before seroconversion.

Polymerase Chain Reaction (PCR)

PCR-based POC platforms detect proviral DNA or viral RNA from FeLV and FIV. For FeLV, PCR targeting the gag or env genes can identify proviral DNA in peripheral blood mononuclear cells, enabling detection of regressive and latent infections that are antigen-negative. For FIV, PCR targeting the pol or gag genes detects proviral DNA and is useful in kittens, vaccinated cats, and cats in the acute seronegative phase. Real-time quantitative PCR (qPCR) provides viral load quantification, which correlates with disease progression and prognosis. POC PCR devices integrate nucleic acid extraction, amplification, and detection in a single cartridge, with results available in 30 to 60 minutes. Sensitivity of PCR for FeLV proviral DNA is greater than 95%, while specificity approaches 100% [7, 13]. For FIV, PCR sensitivity is approximately 90% to 95%, with specificity exceeding 98% [11]. PCR is the only method that can definitively confirm regressive FeLV infection and differentiate vaccine-induced FIV antibodies from natural infection.

Lateral Flow Immunoassays

Lateral flow immunoassays (LFIAs) are single-use, membrane-based test strips that detect FeLV p27 antigen and FIV antibodies via capillary flow and gold nanoparticle-conjugated antibodies. The sample is applied to a sample pad, migrates through a conjugate pad containing labeled detection antibodies, and flows across a nitrocellulose membrane with immobilized capture reagents. A visible line forms at the test zone if the target analyte is present. LFIAs are inexpensive, require no instrumentation, and produce results in 10 to 20 minutes. Their sensitivity for FeLV p27 antigen ranges from 85% to 95%, and specificity from 90% to 98% [9, 14]. For FIV antibody detection, sensitivity is approximately 80% to 90%, with specificity around 95% [11]. LFIAs are less sensitive than SNAP ELISA and PCR, particularly in low-viral-load or early-infection scenarios. They are best suited for screening in low-resource settings or as a secondary confirmatory test.

Comparative Performance and Workflow

The following table summarizes the key performance characteristics of the three POC modalities.

Interpretation of Discordant Results

Discordant results arise when two or more testing modalities yield conflicting outcomes. Common scenarios include:

1. FeLV antigen-positive, PCR-negative: This pattern may indicate a false-positive antigen result due to nonspecific binding or recent vaccination with a killed FeLV vaccine. Alternatively, it could represent a transient antigenemia in a regressive infection where proviral load is below the PCR detection limit. Repeat testing with a different modality or after 4 to 6 weeks is recommended.

2. FeLV antigen-negative, PCR-positive: This discordance is characteristic of regressive FeLV infection, where proviral DNA is present but p27 antigen is not produced. It can also occur during the early eclipse phase of infection before antigenemia develops. PCR is the gold standard for confirming regressive infection [7, 13].

3. FIV antibody-positive, PCR-negative: This result is common in vaccinated cats, as killed FIV vaccines induce antibodies without proviral integration. It can also occur in kittens with maternal antibodies or in cats that have cleared the infection. PCR is necessary to confirm true infection.

4. FIV antibody-negative, PCR-positive: This pattern is seen during the acute phase of FIV infection before seroconversion, which can take 2 to 8 weeks. It may also occur in cats with advanced immunodeficiency and antibody depletion. Repeat serology after 4 to 6 weeks is advised.

A structured decision tree for managing discordant results is presented below.

flowchart TD
    A[Initial POC Test: SNAP ELISA or LFIA], > B{Result}
    B, >|FeLV Ag+ / FIV Ab+| C[Confirm with PCR]
    B, >|FeLV Ag- / FIV Ab-| D[Low risk: No further action]
    B, >|Discordant| C
    C, > E{PCR Result}
    E, >|FeLV PCR+| F[Diagnose FeLV infection]
    E, >|FeLV PCR-| G[Likely false positive Ag; repeat in 4-6 weeks]
    E, >|FIV PCR+| H[Diagnose FIV infection]
    E, >|FIV PCR-| I[Likely vaccine or maternal Ab; no infection]
    F, > J[Clinical staging and management]
    H, > J

Clinical Management of FeLV and FIV Infections

Antiviral Therapy

Antiviral agents for feline retroviruses are limited but expanding. Zidovudine (AZT), a nucleoside reverse transcriptase inhibitor, has demonstrated in vitro activity against both FeLV and FIV. In vivo, AZT reduces viral load and improves clinical signs in FIV-infected cats, but its efficacy in FeLV infection is less pronounced. Dose-dependent bone marrow suppression is a notable adverse effect. Tenofovir, another nucleotide reverse transcriptase inhibitor, has shown activity against FIV in vitro but clinical data remain sparse.

The nucleoside analog GS-441524, a prodrug of the active triphosphate that inhibits RNA-dependent RNA polymerase, has been used extensively for feline infectious peritonitis (FIP) caused by feline coronavirus. Recent studies have explored its off-label use in retrovirus-positive cats with concurrent FIP, with some evidence of improved outcomes [5]. However, GS-441524 is not licensed for FeLV or FIV treatment, and its antiviral activity against retroviruses is not well characterized.

Raltegravir, an integrase strand transfer inhibitor, has been evaluated in FIV-infected cats and shown to reduce proviral load. Its use is limited by cost and availability. Interferon omega (feline interferon omega) has immunomodulatory and antiviral properties and has been used adjunctively in FeLV and FIV management, though controlled trials are lacking.

Immunomodulators

Immunomodulatory therapy aims to enhance host immune responses and reduce secondary infections. Feline interferon omega, administered orally or parenterally, has been associated with improved clinical scores and reduced viral load in some studies. Recombinant feline interleukin-2 has been investigated but is not widely available. Lymphocyte T-cell immunomodulator (LTCI), a bovine-derived glycoprotein, has shown promise in increasing CD4+ counts in FIV-infected cats. However, robust clinical trial data are limited.

Supportive care, including nutritional support, parasite control, and vaccination against common pathogens (e.g., feline herpesvirus, calicivirus, panleukopenia), remains the cornerstone of management. Cats with progressive FeLV infection or symptomatic FIV infection should be housed indoors to reduce exposure to opportunistic pathogens and prevent transmission.

Prognostic Considerations

Long-term survival in retrovirus-infected cats is highly variable. A twenty-year retrospective study of FIV- and FeLV-infected cats in a sanctuary setting demonstrated that FeLV infection significantly reduced median survival time compared to FIV infection alone [1]. Coinfection with FeLV and FIV carries a worse prognosis than either infection alone. Regular monitoring of viral load, hematologic parameters, and clinical status is essential for adjusting therapeutic strategies.

Emerging Technologies and Future Directions

Microfluidic lab-on-a-chip platforms and electrochemical biosensors are under development for feline retrovirus detection. These technologies offer the potential for multiplexed detection of FeLV p27 antigen, FIV antibodies, and proviral DNA in a single sample with high sensitivity and rapid turnaround. CRISPR-based diagnostics, leveraging Cas12 or Cas13 nucleases, have been applied to other veterinary viruses and could be adapted for FeLV and FIV detection. Integration with smartphone-based readers and cloud-based data management systems may further enhance POC capabilities in field settings.

Conclusion

Point-of-care testing for FeLV and FIV has evolved to include SNAP ELISA, PCR, and lateral flow immunoassays, each with distinct advantages and limitations. SNAP ELISA remains the most widely used screening tool due to its speed and high sensitivity for antigen and antibody detection. PCR is indispensable for resolving discordant results, detecting regressive FeLV infection, and confirming FIV infection in vaccinated or early-stage cats. Lateral flow assays offer a low-cost alternative for screening but with reduced sensitivity. Clinical management relies on accurate diagnosis, antiviral therapy where indicated, immunomodulation, and supportive care. Continued advances in POC molecular diagnostics and therapeutic agents will improve outcomes for retrovirus-infected cats.

References

[1] Castillo-Aliaga C, Dunham S, McCallum-Chanter H, et al. Twenty-year lifetime histories of FIV- and FeLV-infected cats in a sanctuary in the UK indicate an effect of retroviral infection on longevity. Vet Rec. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42216781/

[2] Černá P, Ross E, Visser L, et al. Descriptive assessment of cardiac changes in cats with feline infectious peritonitis. J Vet Intern Med. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42139320/

[3] Šolaja S, Milićević V, Glišić D, et al. Molecular insights into domestic cat hepatitis B virus linking genome to function. Vet Res Commun. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42068381/

[4] Lacerda WK, Fernandes ALP, de Sousa MS, et al. Multiple congenital malformations in a litter of feline fetuses associated with gestational exposure to a synthetic estrus-suppressing progestin. BMC Vet Res. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42050592/

[5] Van der Walt M, Jones SE, Levy JK, et al. Clinical Features and Outcomes of Treatment for Effusive Feline Infectious Peritonitis with GS-441524 in Seventeen Retrovirus-Positive Cats. Pathogens. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41901790/

[6] Kim HJ, Heo R, Choi EW. A Retrospective Investigation of 28 Cats with Intermediate- to Large-Cell Lymphoma Treated with Lomustine and Prednisolone as a First-Line Chemotherapy. Animals (Basel). 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41897966/

[7] Pimentel PAB, Giuliano A, da Costa FVA, et al. Corrigendum to Feline lymphoma associated with feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) infections in Brazil- Systematic review. Vet Anim Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41835954/

[8] Buchta K, Meunier SM, Felten S, et al. Large-cell lymphoma in four cats after successful treatment of feline infectious peritonitis with oral GS-441524: a novel clinical observation. J Feline Med Surg. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41807351/

[9] de Almeida PM, Belas A, Nogueira P, et al. Prevalence of feline leukemia virus infection and associated diseases in a Portuguese domestic cat population: A 4.5-year cross-sectional study. PLoS One. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41505408/

[10] Jania B, Andraszek K, Wójcik E, et al. The use of selected electrophoretic techniques to assess the health of domestic cats (Felis catus). J Vet Res. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41497461/

[11] Aftab G, Arab P, Faranoush P. A Comparative Study on the Impact of FIV and FeLV Infection on the Ocular Microbiota in Persian Cats: Insights From Co-Infection and Single Infections. Vet Med Int. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41497367/

[12] van Duijl J, Valtolina C, Hulsman A, et al. Recurrent pyothorax in a cat caused by Candida albicans. JFMS Open Rep. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41346446/

[13] Wenk J, Meli ML, Meunier SM, et al. Viral Coinfections Potentially Associated with Feline Chronic Gingivostomatitis in Cats with Feline Infectious Peritonitis. Viruses. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41305526/

[14] Didkowska A, Matusik K, Klich D, et al. The prevalence of highly-pathogenic viruses in European wildcat and Eurasian Lynx in Poland. Vet Res Commun. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41240245/

[15] Silva JC, de Freitas Silva GM, Carvalho LRRA. Bilateral conjunctival sporotrichosis in a domestic cat: case report. Front Vet Sci. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41195078/